Coherus BioSciences Inc (Coherus) is a commercial-stage biopharmaceutical company that focuses on research, development and commercialization of innovative immunotherapies to treat cancer. Its pipeline products include LOQTORZI (toripalimab-tpzi), a novel PD-1 inhibitor, that treats Nasopharyngeal Carcinoma; Casdozokitug is an investigational recombinant human IgG1 monoclonal antibody for Hepatocellular Carcinoma and Non-Small Cell Lung Cancer; CHS-114 and CHS-1000, which targets Solid Tumors. The company also develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor and YUSIMRY, a biosimilar to Humiram which treats inflammatory diseasesCoherus is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200, Redwood City, California, 94065
Website
www.coherus.com
Telephone
1 650 6493530
No of Employees
306
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CHRS (NASD)
Revenue (2022)
$257.2M
21.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
18.5%
(2022 vs 2021)
Market Cap*
$233.3M
Net Profit Margin (2022)
XYZ
33.1%
(2022 vs 2021)
* As of and is in US$
Coherus BioSciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | UDENYCA |
| toripalimab-tpzi: Nasopharyngeal Carcinoma | YUSIMRY |
| CHS-006: Hepatocellular Carcinoma and Non-Small Cell Lung Cancer | CIMERLI |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company and Pharmakon Advisors entered into an agreement to modify the terms of its loan agreement. |
| 2024 | New Products/Services | In February, the company introduced UDENYCA ONBODY. |
| 2024 | Contracts/Agreements | In January, the company entered into an agreement to sell CIMERLI (ranibizumab-eqrn) to Sandoz for US$170 million. |
Competitor Comparison
| Key Parameters | Coherus BioSciences Inc | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc | AbbVie Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United States of America | United States of America | United States of America |
| City | Redwood City | Basel | Kenilworth | New York | North Chicago |
| State/Province | California | - | New Jersey | New York | Illinois |
| No. of Employees | 306 | 103,605 | 72,000 | 88,000 | 50,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dennis M. Lanfear | Chairman; President; Chief Executive Officer | Executive Board | 2010 | 68 |
| Rosh Dias, MD. | Chief Medical Officer | Senior Management | 2022 | - |
| Vladimir Vexler, Ph.D. | Chief Scientific Officer | Senior Management | 2018 | 64 |
| Andy Rittenberg | Executive Vice President; General Counsel | Senior Management | 2024 | - |
| Scott Saywell | Executive Vice President - Corporate Development | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward